Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer

Journal of Urology

Volumn 188, Issue 4, 2012, Pages 1131-1136

  Tosoian, Jeffrey J ^a   Loeb, Stacy ^a   Feng, Zhaoyong ^a   Isharwal, Sumit ^a   Landis, Patricia ^a   Elliot, Debra J ^a   Veltri, Robert ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Carter, H Ballentine ^a   Trock, Bruce ^a   Sokoll, Lori J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

biopsy; prostate specific antigen; prostatic neoplasms; watchful waiting

Indexed keywords

PROENZYME PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 84866090485     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.06.009     Document Type: Article

References (30)

1. American Cancer Society Cancer Facts & Figures 2012 2012 American Cancer Society Atlanta
2. H.J. Linton, L.S. Marks, L.S. Millar Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease Clin Chem 49 2003 253
3. S.D. Mikolajczyk, H.G. Rittenhouse Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer Keio J Med 52 2003 86
4. J. Peter, C. Unverzagt, T.N. Krogh Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry Cancer Res 61 2001 957
5. S.D. Mikolajczyk, L.S. Millar, T.J. Wang A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue Cancer Res 60 2000 756
6. L.J. Sokoll, D.W. Chan, S.D. Mikolajczyk Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis Urology 61 2003 274
7. W.J. Catalona, G. Bartsch, H.G. Rittenhouse Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 2003 2181
8. F.H. Jansen, R.H. van Schaik, J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921
9. W.J. Catalona, A.W. Partin, M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
10. L.J. Sokoll, M.G. Sanda, Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193
11. W.J. Catalona, G. Bartsch, H.G. Rittenhouse Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen J Urol 171 2004 2239
12. D.V. Makarov, S. Isharwal, L.J. Sokoll Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer Clin Cancer Res 15 2009 7316
13. S. Isharwal, D.V. Makarov, L.J. Sokoll ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program Urology 77 2011 763
14. H.B. Carter, P.C. Walsh, P. Landis Expectant management of nonpalpable prostate cancer with curative intent: preliminary results J Urol 167 2002 1231
15. J.J. Tosoian, B.J. Trock, P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185
16. J.I. Epstein, P.C. Walsh, M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
17. J. Mohler, R.R. Bahnson, B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162
18. L.D. Fisher, D.Y. Lin Time-dependent covariates in the Cox proportional-hazards regression model Annu Rev Public Health 20 1999 145
19. J. Twisk, W. de Vente Attrition in longitudinal studies How to deal with missing data J Clin Epidemiol 55 2002 329
20. R.B. Newson Comparing the predictive power of survival models using Harrell's c or Somers' D Stata J 10 2010 339
21. L. Klotz, L. Zhang, A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
22. C. Warlick, B.J. Trock, P. Landis Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 98 2006 355
23. R.C. van den Bergh, E.W. Steyerberg, A. Khatami Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 116 2010 1281
24. D.C. Miller, S.B. Gruber, B.K. Hollenbeck Incidence of initial local therapy among men with lower-risk prostate cancer in the United States J Natl Cancer Inst 98 2006 1134
25. K.S. Tseng, P. Landis, J.I. Epstein Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779
26. J.J. Tosoian, S. Loeb, A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534
27. M.A. Khan, A.W. Partin, H.G. Rittenhouse Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml J Urol 170 2003 723
28. L.J. Sokoll, Y. Wang, Z. Feng [-2]Proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study J Urol 180 2008 539
29. B.V. Le, C.R. Griffin, S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355
30. T.B. Sheridan, H.B. Carter, W. Wang Change in prostate cancer grade over time in men followed expectantly for stage T1c disease J Urol 179 2008 901